Free Trial

National Bank of Canada FI Sells 49,005 Shares of Amedisys, Inc. (NASDAQ:AMED)

Amedisys logo with Medical background

National Bank of Canada FI decreased its position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 65.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,379 shares of the health services provider's stock after selling 49,005 shares during the quarter. National Bank of Canada FI owned about 0.08% of Amedisys worth $2,453,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Allianz Asset Management GmbH increased its position in shares of Amedisys by 146.0% during the fourth quarter. Allianz Asset Management GmbH now owns 39,855 shares of the health services provider's stock worth $3,789,000 after buying an additional 23,655 shares during the period. Water Island Capital LLC increased its holdings in Amedisys by 185.0% in the fourth quarter. Water Island Capital LLC now owns 710,697 shares of the health services provider's stock worth $67,559,000 after purchasing an additional 461,368 shares in the last quarter. Nomura Holdings Inc. lifted its stake in Amedisys by 604.2% in the fourth quarter. Nomura Holdings Inc. now owns 49,297 shares of the health services provider's stock valued at $4,686,000 after buying an additional 42,297 shares during the period. Norges Bank bought a new stake in shares of Amedisys in the 4th quarter valued at $34,032,000. Finally, SG Americas Securities LLC increased its stake in Amedisys by 41.6% in the second quarter. SG Americas Securities LLC now owns 38,315 shares of the health services provider's stock valued at $3,517,000 after purchasing an additional 11,264 shares in the last quarter. Institutional investors own 94.36% of the company's stock.


Wall Street Analysts Forecast Growth

AMED has been the topic of a number of research reports. William Blair downgraded Amedisys from an "outperform" rating to a "market perform" rating in a research note on Monday, July 1st. Cantor Fitzgerald reissued a "neutral" rating and issued a $101.00 price target on shares of Amedisys in a research report on Thursday, July 25th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Amedisys from a "buy" rating to a "hold" rating and set a $101.00 price target for the company. in a research note on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, Amedisys presently has an average rating of "Hold" and a consensus price target of $100.67.

Get Our Latest Analysis on AMED

Amedisys Stock Up 0.1 %

Shares of AMED stock traded up $0.08 during trading hours on Thursday, reaching $96.80. The company had a trading volume of 185,349 shares, compared to its average volume of 327,015. The business has a fifty day simple moving average of $97.75 and a 200-day simple moving average of $94.66. Amedisys, Inc. has a 12 month low of $89.55 and a 12 month high of $98.95. The company has a market cap of $3.16 billion, a price-to-earnings ratio of -151.25, a price-to-earnings-growth ratio of 1.90 and a beta of 0.78. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.16 and a quick ratio of 1.16.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its quarterly earnings data on Wednesday, July 24th. The health services provider reported $1.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.22 by $0.10. The firm had revenue of $591.19 million for the quarter, compared to the consensus estimate of $579.34 million. Amedisys had a net margin of 4.02% and a return on equity of 12.39%. On average, research analysts expect that Amedisys, Inc. will post 4.66 earnings per share for the current fiscal year.

Amedisys Company Profile

(Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Featured Articles

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

→ Forget Trump and Kamala (From Investors Alley) (Ad)

Should you invest $1,000 in Amedisys right now?

Before you consider Amedisys, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.

While Amedisys currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Is Palantir Heading for a $50 Price Target?
Rate Cuts Fuel Volatility: How Long Could it Last?
SMCI Stock: Is a Rebound Coming?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines